

1 **Antibodies against type-I Interferon: detection and association with** 2 **severe clinical outcome in COVID-19 patients**

3 Goncalves David¹, Mezidi Mehdi², Bastard Paul^{3,4,5}, Perret Magali^{1,6}, Saker Kahina⁷, Fabien Nicole¹,
4 Pescarmona Rémi^{1,6}, Lombard Christine¹, Walzer Thierry⁶, Casanova Jean-Laurent^{3,4,5}, Belot
5 Alexandre^{6,8,9}, Richard Jean-Christophe², Trouillet-Assant Sophie^{6,7}

6 ¹ Immunology Department, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France.

7 ² Lyon University, CREATIS, CNRS UMR5220, Inserm U1044, INSA, Lyon, France, Intensive Care Unit,
8 Hospices Civils de Lyon, Lyon, France

9 ³Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker
10 Hospital for Sick Children, Paris, France.

11 ⁴University of Paris, Imagine Institute, Paris, France.

12 ⁵St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller
13 University, New York, NY, USA.

14 ⁶ International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308,
15 ENS, UCBL, Lyon, France

16 ⁷ Infective Agents Institute, Hospices Civils de Lyon, Lyon, France

17 ⁸ National Referee Centre for Rheumatic and AutoImmune and Systemic diseases in childrEn (RAISE),
18 France

19 ⁹ Pediatric Nephrology, Rheumatology, Dermatology Unit, Hospices Civils de Lyon, France

20 **Corresponding author:**

21 Sophie Trouillet-Assant, PhD

22 Centre Hospitalier Lyon Sud, Pierre-Bénite

23 69495 Lyon, France.

24 Phone: + 33 (0) 472 00 37 70. sophie.assant@chu-lyon.fr

25

26 **Conflict of interest** : All authors declare no conflict of interest

27 **Funding** : This research is being supported by Hospices Civils de Lyon and by Fondation des Hospices

28 Civils de Lyon.

29

30 **Abstract**

31 **Objectives** Impairment of type I interferon (IFN-I) immunity has been reported in critically ill COVID-
32 19 patients. This defect can be explained by the presence of circulating autoantibodies against IFN-I.

33 We set out to improve the detection and the quantification of such antibodies (Abs) in a cohort of
34 severe Covid-19 patients, in an effort to better document the prevalence of these Abs as the
35 pandemic evolves and how they correlate with the clinical course of the disease.

36 **Methods** Anti-IFN- α Abs was investigated 84 critical COVID-19 patients who were admitted to ICU at
37 the Lyon University Hospital, France with a commercially available kit (Thermo-Fisher).

38 **Results** Twenty-one patients out of 84 (25%) had anti-IFN α 2 Ab above cut-off (>34ng/mL) in sera. A
39 neutralizing activity against IFN- α 2 was evidenced in 15 of them, suggesting that 18% of patients
40 were positive for neutralizing anti-IFN- α and - ω auto-Abs. In addition, in most of patients with
41 neutralizing IFN-I Abs, we noticed an impairment of the IFN-I response. However, we did not find any
42 difference in terms of clinical characteristics or outcome between critical COVID-19 patients “with or
43 without” neutralizing anti-IFN- α 2 auto-Abs in these conditions. Finally, we detected anti-type I IFN
44 auto-Abs in COVID-19 patients’ sera were detected throughout the ICU stay.

45 **Conclusions** We report that 18% of severe COVID-19 patients were positive for these Anti-Type-I IFN
46 Abs, confirming the detrimental role of these Abs on the antiviral response. Our results further
47 support the use of recombinant type I IFNs not targeted by the auto-Abs (e.g., IFN-b) in COVID-19
48 patients with an impaired IFN-I response.

49

50 **Keywords** – Type I interferon, COVID-19, SARS-CoV2 virus, Intensive care unit, viral infection, auto-
51 antibodies

52

53

54 **Introduction**

55 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) infection leads to coronavirus disease
56 19 (COVID 19), a disease with a wide spectrum of clinical presentations, including severe pneumonia.
57 The anti-SARS-CoV-2 immune response has been extensively studied and defects of antiviral
58 mechanisms have been linked to disease severity. In particular, impairment of type I interferon (IFN-
59 I) immunity has been reported in critically ill COVID-19 patients infected during the first wave of the
60 pandemics. This defect was explained either by inborn genetic defects of the IFN-I pathway or by the
61 presence of circulating autoantibodies against 14 or the 17 individual IFN-I (1-4). These auto-Abs
62 against type I IFNs were also found in a third of patients from a small international cohort who had
63 suffered from severe adverse events following Yellow Fever vaccination (YFV-17D) vaccination (5).
64 These findings advocate for the development of diagnostic tools in routine laboratories. Here, we set
65 out to improve the detection and the quantification of such antibodies (Abs) in a cohort of severe
66 Covid-19 patients, in an effort to better document the prevalence of these Abs as the pandemics
67 evolves and how they correlate with the clinical course of the disease.

68

69 **Results**

70 Our cohort comprised 84 critical COVID-19 patients who were admitted to ICU at the Lyon University
71 Hospital, France between September and December 2020. A local ethical committee for biomedical
72 research (Comité de Protection des Personnes HCL, Supplemental material and methods) approved
73 our study. The presence of anti IFN- α 2 Abs was investigated with a commercially available kit
74 (Thermo-Fisher). We first sought to determine a positive cut-off value for Ab detection by performing
75 measurements in 76 putative control sera ie from healthy donors retrieved before the Covid19
76 outbreak. The mean value +3SD of these measurements gave a cut-off value at 34ng/mL. We then
77 assessed the presence of IFN- α 2 Abs in putative positive sera, ie sera from patients with autoimmune
78 polyendocrinopathy type 1 syndrome (APS-1), a condition known to be associated with anti-cytokine
79 autoAbs. All 11 patients tested were positive for anti-IFN- α 2 autoAbs (>100ng/mL for all of them).
80 We also evaluated the presence of anti-IFN- α 2 autoAbs in 10 mild COVID-19 healthcare workers for
81 which no autoAb was found.

82 We then measured anti-IFN α 2 Ab levels in sera from the 84 COVID-19 patients in our ICU cohort, and
83 values above cut-off (>34ng/mL) were found in 21 patients. The neutralizing capacity of patients'
84 sera against IFN- α and IFN- ω was then evaluated as previously described (5). A neutralizing activity
85 was evidenced in 15 out the 21 sera with IFN- α 2 Abs, suggesting that 18% of patients were positive
86 for neutralizing anti-IFN- α and - ω auto-Abs (Figure 1A). Importantly, all sera with anti-IFN- α 2 auto-
87 Abs concentrations above 1 μ g/mL potently neutralized IFN- α and - ω in vitro. In addition, in most
88 patients with neutralizing IFN-I Abs, we noticed an impairment of the IFN-I response, as determined
89 by the measurement of i) plasma IFN- α 2 levels using the new digital ELISA technology single-molecule
90 arrays (Simoa) and ii) blood Interferon Stimulating Genes (ISG) expression using the Nanostring
91 nCounter technology in blood samples collected in the first 15 days after symptoms (Figure 1B-C).
92 Moreover, we found no difference in clinical parameters (age, sex ratio, co-morbidity) or outcome
93 (death, O₂ support) between critical COVID-19 patients "with or without" neutralizing anti-IFN- α 2

94 auto-Abs in these conditions (Table 1). Finally, we detected anti-type I IFN auto-Ab in COVID-19
95 patients' sera throughout the ICU stay, as shown in Figure 1D.

96 **Conclusions**

97 A previous study reported that IFN-I auto-Abs were undetectable in 663 individuals with
98 asymptomatic or mild COVID-19 and only detected in 0.33% of healthy individuals (1) whereas we
99 report here that 18% of severe COVID-19 patients were positive for these Abs. This finding further
100 confirms the deleterious role of IFN-I autoAbs in the antiviral immune response, and reciprocally the
101 central importance of the IFN-I pathway. We noticed that only a part of auto-Abs detected were able
102 to neutralize IFN-I in the conditions we used, which confirms previous studies in COVID-19 patients
103 and systemic lupus erythematosus subjects (1, 6). Our results further support the use of recombinant
104 type I IFNs not targeted by the auto-Abs (e.g., IFN-b) or type III IFNs in COVID-19 patients with an
105 impairment of the IFN-I response. First clinical trials evaluating the administration of recombinant
106 IFN-b did not show any beneficial effect in ICU patients (7). Nevertheless, post-hoc analysis have
107 demonstrated the benefit of cytokine therapies (ie IL-1RA or GM-CSF) in a sub cohort of septic shock
108 patients, when initial clinical trials had reported no positive effect (8-11). Moreover, such treatments
109 could be more adapted to selected patients with IFN- α 2 autoAb. Yet, inhaled IFN β was efficient in
110 patients with moderate or severe disease (12) and could be given in ambulatory patients,
111 symptomatic or not, or even in contact cases.

112

113 **Methods**

114 ***Ethics***

115 *Critical COVID-19 patients*

116 Plasma samples and Paxgene® tubes were collected from COVID-19 patients hospitalized in the
117 university hospital of Lyon (Hospices Civils de Lyon), France. Diagnosis of COVID-19 was confirmed in
118 all patients by RT-PCR.

119 All critically ill patients, admitted to ICU, were included in the MIR-COVID study. This study was
120 registered to the French National Data Protection Agency under the number 20-097 and was
121 approved by an ethical committee for biomedical research (*Comité de Protection des Personnes HCL*)
122 under the number N°20-41. In agreement with the General Data Protection Regulation (Regulation
123 (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law n°78-17 on
124 06/01/1978 and Décret n°2019-536 on 29/05/2019), we obtained consent from each patient or his
125 next of kin.

126 *Mild COVID-19 patients*

127 Plasma samples and Paxgene® tubes were collected from symptomatic healthcare workers at SARS-
128 CoV-2 diagnosis. Written informed consent was obtained from all participants; ethics approval was
129 obtained from the national review board for biomedical research in April 2020 (Comité de Protection
130 des Personnes Sud Méditerranée I, Marseille, France; ID RCB 2020-A00932-37), and the study was
131 registered on ClinicalTrials.gov (NCT04341142) (13).

132 *Auto-Abs anti Type I IFN investigation*

133 The presence of anti IFN- α 2 Abs was investigated in plasma with a commercially available kit
134 (Thermo-Fisher). The positive cut-off value for Ab detection was 34ng/mL. The neutralization
135 capacity of these antibodies against IFN- α 2 and $-\omega$ was determined as previously described (5).

136 *Plasma protein quantification*

137 Plasma IFN- α concentrations (fg/ml) were determined by single molecule array (Simoa) using a
138 commercial kit for IFN- α ₂ quantification (Quanterix™, Lexington, MA, USA) on plasma samples of
139 COVID-19 patients. The assay was based on a 3- step protocol using an HD- 1 Analyzer (Quanterix).

140 *IFN score assessment*

141 RNA was extracted from whole blood contained in Paxgene® tubes (Kit PreAnalytix, Qiagen©, SW)
142 and quantified by spectrophotometric assay (Nanodrop 2000, Thermo Scientific™, MA, USA). RNA
143 integrity was then evaluated by Agilent RNA microarray (Agilent Technologies©, Santa Clara, CA,

144 USA). mRNA quantification of 6 ISGs (*interferon alpha inducible protein 27 (IFI27)*, *interferon induced*
145 *protein 44 like (IFI44L)*, *Interferon Induced Protein With Tetratricopeptide Repeats 1 (IFIT1)* , *ISG15*
146 *Ubiquitin Like Modifier (ISG15)*, *Radical S-Adenosyl Methionine Domain Containing 2 (RSAD2)*, *Sialic*
147 *Acid Binding Ig Like Lectin 1 (SIGLEC1)* and 3 housekeeping genes (*Actin Beta (ACTB)*, *Hypoxanthine*
148 *Phosphoribosyltransferase 1 (HPRT1)*, *RNA Polymerase II Subunit A (POLR2A)*), was performed using
149 nanostring technology (Nanostring Technologies©, WA, USA). Data standardization was obtained
150 using the geometric mean of internal control and housekeeping genes count number. Interferon
151 score was calculated as previously described (14).

152

153

154

155 **References**

- 156 1. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies
157 against type I IFNs in patients with life-threatening COVID-19. *Science*. 2021 Oct 23;370(6515).
- 158 2. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I
159 interferon activity and inflammatory responses in severe COVID-19 patients. *Science*. 2020 Aug
160 7;369(6504):718-24.
- 161 3. Trouillet-Assant S, Viel S, Gaymard A, Pons S, Richard JC, Perret M, et al. Type I IFN
162 immunoprofiling in COVID-19 patients. *J Allergy Clin Immunol*. 2020 Jul;146(1):206-8 e2.
- 163 4. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN
164 immunity in patients with life-threatening COVID-19. *Science*. 2020 Oct 23;370(6515).
- 165 5. Bastard P, Michailidis E, Hoffmann HH, Chbihi M, Le Voyer T, Rosain J, et al. Auto-antibodies
166 to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. *J Exp Med*. 2021
167 Apr 5;218(4).
- 168 6. Gupta S, Nakabo S, Chu J, Hasni S, Kaplan M. Association between anti-interferon-alpha
169 autoantibodies and COVID-19 in systemic lupus erythematosus. *medrxiv*. 2020.
- 170 7. Pan H, Peto R, Heno-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al.
171 Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021
172 Feb 11;384(6):497-511.
- 173 8. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and
174 granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. *Crit Care*.
175 2011;15(1):R58.
- 176 9. Opal SM, Fisher CJ, Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory
177 interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind,
178 placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator
179 Group. *Crit Care Med*. 1997 Jul;25(7):1115-24.

- 180 10. Pinder EM, Rostron AJ, Hellyer TP, Ruchaud-Sparagano MH, Scott J, Macfarlane JG, et al.
181 Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis.
182 *Thorax*. 2018 Oct;73(10):918-25.
- 183 11. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1
184 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of
185 Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. *Crit Care Med*. 2016
186 Feb;44(2):275-81.
- 187 12. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy
188 of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a
189 randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med*. 2021 Feb;9(2):196-
190 206.
- 191 13. Trouillet-Assant S, Albert Vega C, Bal A, Nazare JA, Fascia P, Paul A, et al. Assessment of
192 serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric
193 study. *BMJ Open*. 2020 Nov 24;10(11):e041268.
- 194 14. Pescarmona R, Belot A, Villard M, Besson L, Lopez J, Mosnier I, et al. Comparison of RT-qPCR
195 and Nanostring in the measurement of blood interferon response for the diagnosis of type I
196 interferonopathies. *Cytokine*. 2018 Jan;113:446-52.

197
198

199

200 **Figure 1- Anti-Type I IFN antibodies (Abs) in patients with life-threatening COVID-19**

201 A. Auto-Abs against IFN- α_2 concentrations (ng/mL) determined by Thermofisher kit in serum
202 samples collected from COVID-19 patients admitted in ICU (n=84) and COVID-19 patients
203 with mild respiratory symptoms (n=10). Neutral. means auto-Abs with neutralizing capacity
204 against IFN- α and - ω B.C- IFN- α_2 concentrations (fg/mL) (B) and ISG score (C) in plasma and
205 whole blood collected from COVID-19 patients in the first 15 days after symptom onset
206 (critical COVID-19 (n=54) and mild COVID-19 (n=10)) . D- Longitudinal detection of auto-Abs
207 against IFN- α_2 of COVID-19 patients during ICU stay according to time post symptom. Dotted
208 lines represent positive cut-off value (threshold), lower limit of quantification (LLOQ) and
209 upper limit of quantification (ULOQ)

210

211

212


Clinical features	Auto-nAb Negative (n=69)	Auto-nAb Positive (n=15)	P-value
Age	67 [58-72]	65 [55-74]	0.75
Sex male (%)	54 (78%)	13 (87%)	0.72
BMI (kg/m ²)	29 [26-34]	29 [25-32]	0.49
Auto-immune disease	7 (10%)	2 (13%)	0.66
Time between 1 st symptoms and ICU admission (day)	9 [7-12]	10 [7-11]	0.80
Maximal ventilatory support			
• Standard oxygen only	4 (6%)	0 (0%)	0.33
• High flow oxygen only	19 (28%)	7 (47%)	
• Invasive mechanical ventilation	46 (67%)	8 (53%)	
ARDS criteria	44 (64%)	8 (53%)	0.65
Worst PaO ₂ /FiO ₂ day 1 in ICU (mm Hg)	75 [62-103]	89 [62-116]	0.40
ECMO	15 (22%)	2 (13%)	0.72
SOFA Day 1 in ICU	4 [3-8]	3 [2-5]	0.11
SAPS2 Day 1 in ICU	40 [31-47]	43 [38-48]	0.41
Vasopressor requirement in ICU	45 (65%)	9 (60%)	0.77
Renal replacement therapy in ICU	27 (39%)	4 (27%)	0.56
ICU length of stay (day)	13 [7-35]	13 [6-24]	0.74
ICU mortality	29 (42%)	5 (33%)	0.58

213


214 **Table 1 - Clinical characteristics of COVID-19 patients in intensive care unit**

215 Data are median [IQR] or count (percentage). Mann-Whitney and Fisher tests were used for quantitative and qualitative variables, respectively. ICU -
216 Intensive Care Unit, BMI - Body Mass Index, nAb – neutralizing Auto-Abs against IFN- α


A




B



C



D



- Positive neutralizing Ab anti-IFN
- Positive Ab anti-IFN
- ▲ Negative neutralizing Ab anti-IFN
- Negative Ab anti-IFN